Display Settings:

Format

Send to:

Choose Destination
Curr Cancer Drug Targets. 2010 Feb;10(1):19-26.

Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets.

Author information

  • 1Gene Expression Core--Human Molecular Genetics Laboratory, Institute of Genetics and Biophysics, CNR Naples Italy.

Abstract

Malignant mesothelioma (MM) is a rare, highly aggressive tumor that arises from the surface serosal cells (pleural, peritoneal and pericardial cavities). Epidemiological and clinical data show that there is an association between asbestos exposure and MM development, even if the exact mechanism whereby asbestos induces MM is unknown. The continuing identification and elucidation of the molecular defects involved in mesothelioma pathogenesis and progression should lead to better disease control and greater therapeutic options in the near future. Goal of this article is to summarize the most recent advances in molecular pathogenesis of mesothelioma with particular emphasis on genes that could be considered as biomarkers or therapeutic targets and discuss possible clinical implications of these findings.

PMID:
20088796
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Write to the Help Desk